Human papillomavirus types 6 and 11 seropositivity: Risk factors and association with ano-genital warts among homosexual men

Journal of Infection

Volumn 66, Issue 6, 2013, Pages 503-511

  Poynten, I Mary ^a   Waterboer, Tim ^b   Jin, Fengyi ^a   Templeton, David J ^a,c   Prestage, Garrett ^a   Donovan, Basil ^a,d   Pawlita, Michael ^b   Fairley, Christopher K ^e   Garland, Suzanne M ^e   Grulich, Andrew E ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d SYDNEY EYE HOSPITAL   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Anal warts; Homosexual; HPV11; HPV6; Human papillomavirus; MSM

Indexed keywords

ANTIBODY; CAPSID PROTEIN L1 ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; AUSATRALIAN; CHLAMYDIA; COHORT ANALYSIS; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; DISEASE ASSOCIATION; ETHNIC GROUP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 6; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; NONHUMAN; PAPILLOMAVIRUS INFECTION; PROSPECTIVE STUDY; RISK ASSESSMENT; SEROCONVERSION; SEROINCIDENCE; SEROPREVALENCE; SEXUAL BEHAVIOR; SEXUALITY; VACCINATION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, VIRAL; AUSTRALIA; CONDYLOMATA ACUMINATA; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 6; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES;

EID: 84876833129     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2013.03.005     Document Type: Article

References (42)

1. Hartwig S., Syrjänen S., Dominiak-Felden G., Brotons M., Castellsagué X. Estimation of the epidemiological burden of human papillomavirus-related cancers and nonmalignant diseases in men in Europe: a review. BMC Cancer 2012, 12:30.
2. Lacey C., Lowndes C., Shah K. Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006, 24. S3:S3/35-S3/41.
3. Giuliano A., Tortolero-Luna G., Ferrer E., Burchell A., de Sanjose S., Kruger Kjaer S., et al. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine 2008, 26S:K17-K28.
4. Partridge J., Koutsky L. Genital human papillomavirus infection in men. Lancet Infectious Diseases 2006, 6:21-31.
5. Garland S., Steben M., Sings H., James M., Lu S., Railkar R., et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11,16, and 18) vaccine. Journal of Infectious Diseases 2009, 199:805-814.
6. Winer R., Koutsky L. Genital human papillomavirus infection. Sexually transmitted diseases 2008, 489-508. McGraw-Hill Company, China. 4th ed. K. Holmes (Ed.).
7. Pirotta M., Stein A., Conway E., Harrison C., Britt H., Garland S. Genital wart incidence and health care resource utilisation in Australia. Sexually Transmitted Infections 2010, 86:181-186.
8. Desai S., Wetten S., Woodhall S., Peters L., Hughes G., Soldan K. Genital warts and cost of care in England. Sexually Transmitted Infections 2011, 87:464-468.
9. Pirotta M., Ung L., Stein A., Conway E., Mast T., Fairley C., et al. The psychosocial burden of HPV-related disease and screening interventions. Sexually Transmitted Infections 2009, 85:508-513.
10. Donovan B., Franklin N., Guy R., Grulich A., Regan D., Ali H., et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infectious Diseases 2011, 11:39-44.
11. Vajdic C., van Leeuwen M., Jin F., Prestage G., Medley G., Hillman R., et al. Anal human papillomavirus genotype diversity and co-infection in a community-based sample of homosexual men. Sexually Transmitted Infections 2009, 85:330-335.
12. Lu B., Viscidi R., Lee J., Wu Y., Villa L., Lazcano-Ponce E., et al. Human papillomavirus (HPV) 6, 11, 16 and 18 seroprevalence is associated with sexual practice and age: results from the multi-national HPV infection in men study (HIM study). Cancer Epidemiology, Biomarkers and Prevention 2011, 20:990-1002.
13. Palefsky J., Giuliano A., Goldstone S., Moreira E.D., Aranda C., Jessen H., et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. New England Journal of Medicine 2011, 365:1576-1585.
14. Quinn R., Salvatierra J., Solari V., Calderon M., Ton T., Zunt J. Human papillomavirus infection in Men who have Sex with Men in Lima, Peru. AIDS Research and Human Retroviruses 2012, 28.
15. Jin F., Prestage G., Kippax S., Pell C., Donovan B., Templeton D., et al. Risk factors for genital and anal warts in a prospective cohort of HIV-negative homosexual men: the HIM study. Sexually Transmitted Diseases 2007, 34:488-493.
16. Skaaby S., Kofoed K. Anogenital warts in Danish men who have sex with men. International Journal of STD & AIDS 2011, 22:214-217.
17. Anic G., Lee J., Villa L., Lazcano-Ponce E., Gage C., Silva R., et al. Risk factors for incident condyloma in a multinational cohort of men: the HIM study. Journal of Infectious Diseases 2012, 205:789-793.
18. Palefsky J., Shiboski S., Moss A. Risk factors for anal human papillomavirus infection and anal cytologic abnormalities in HIV-positive and HIV-negative homosexual men. Journal of Acquired Immune Deficiency Syndrome 1994, 7:599-606.
19. Goldstone S., Palefsky J., Giuliano A., Moreira E., Aranda C., Jessen H., et al. Prevalence of and risk factors for human papillomavirus (HPV) infection among HIV-seronegative men who have sex with men. Journal of Infectious Diseases 2011, 203:66-74.
20. Heiligenberg M., Michael K., Kramer M., Pawlita M., Prins M., Coutinho R., et al. Seroprevalence and determinants of eight high-risk human papillomavirus types in homosexual men, heterosexual men, and women: a population-based study in Amsterdam. Sexually Transmitted Diseases 2010, 37:672-680.
21. Höpfl R., Petter A., Thaler P., Sarcletti M., Widschwendter A., Zangerle R. High prevalence of high risk human papillomavirus-capsid antibodies in human immunodeficiency virus-seropositive men: a serological study. BMC Infectious Diseases 2003, 3.
22. Jin F., Prestage G., Mao L., Kippax S., Pell C., Donovan B., et al. Transmission of herpes simplex virus types 1 and 2 in a prospective cohort of HIV-negative gay men: the Health in Men study. Journal of Infectious Diseases 2006, 194:561-570.
23. Prestage G., Mao L., Fogarty A., Van de Ven P., Kippax S., Crawford J., et al. How has the sexual behaviour of gay men changed since the onset of AIDS: 1986-2003. Australian and New Zealand Journal of Public Health 2005, 29:530-535.
24. Poynten I., Jin F., Templeton D., Prestage G., Donovan B., Pawlita M., et al. Prevalence, incidence and risk factors for HPV16 seropositivity in Australian homosexual men. Sexually Transmitted Diseases 2012, 39:726-732.
25. Waterboer T., Sehr P., Michael K., Franceschi S., Nieland J., Joos T., et al. Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clinical Chemistry 2005, 51:1845-1853.
26. Clifford G., Shin H., Oh J., Waterboer T., Ju Y., Vaccarella S., et al. Serologic response to oncogenic human papillomavirus types in male and female University students in busan, South Korea. Cancer Epidemiology, Biomarkers and Prevention 2007, 16:1874-1879.
27. Sehr P., Muller M., Hopfl R., Widschwendter A., Pawlita M. HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase. Journal of Virological Methods 2002, 106:61-70.
28. Sehr P., Zumbach K., Pawlita M. A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology. Journal of Immunological Methods 2001, 254:153-162.
29. Waterboer T., Sehr P., Pawlita M. Suppression of non-specific binding in serological Luminex assays. Journal of Immunological Methods 2006, 309:200-204.
30. Carter J., Paulson K., Wipf G., Miranda D., Madeleine M., Johnson L., et al. Association of Merkel cell polyomavirus - specific antibodies with Merkel cell carcinoma. Journal of the National Cancer Institute 2009, 101:1510-1522.
31. Herrero R., Castellsagué X., Pawlita M., Lissowska J., Kee F., Balaram P., et al. Human papillomavirus and oral cancer: the International agency for research on cancer multicenter study. Journal of the National Cancer Institute 2003, 95:1772-1783.
32. Rizk R., Christensen N., Michael K., Müller M., Sehr P., Waterboer T., et al. Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. Journal of General Virology 2008, 89:117-129.
33. Hagensee M., Kiviat N., Critchlow C., Hawes S., Kuypers J., Holte S., et al. Seroprevalence of Human Papillomavirus types 6 and 16 capsid antibodies in homosexual men. Journal of Infectious Diseases 1997, 176:625-631.
34. Hariri S., Dunne E., Sternberg M., Unger E., Meadows K., Karem K., et al. Seroepidemiology of human papillomavirus type 11 in the United States: results from the third national health and nutrition examination survey, 1991-1994. Sexually Transmitted Diseases 2008, 35:298-303.
35. Newall A., Brotherton J., Quinn H., McIntyre P., Backhouse J., Gilbert L., et al. Population seroprevalence of Human papillomavirus types 6, 11, 16, and 18 in men, women and children in Australia. Clinical Infectious Diseases 2008, 46:1647-1655.
36. Markowitz L., Sternberg M., Dunne E., McQuillan G., Unger E. Seroprevalence of human papillomavirus types 6, 11, 16 and 18 in the United States: national health and nutrition examination survey 2003-2004. Journal of Infectious Diseases 2009, 200:1059-1067.
37. Dunne E., Nielson C., Stone K., Markowitz L., Giuliano A. Prevalence of HPV infection among men: a systematic review of the literature. Journal of Infectious Diseases 2006, 194:1044-1057.
38. Lu B., Viscidi R., Wu Y., Nyitray A., Villa L., Lazcano-Ponce E., et al. Seroprevalence of human papillomavirus (HPV) type 6 and 16 vary by anatomic site of HPV infection in men. Cancer Epidemiology Biomarkers and Prevention 2012, 9:1542-1546.
39. Prestage G., Kippax S., Jin F., Frankland A., Imrie J., Grulich A., et al. Does age affect sexual behaviour among gay men in Sydney, Melbourne and Brisbane, Australia?. AIDS Care 2009, 21:1098-1105.
40. Edelstein Z., Carter J., Garg R., Winer R., Feng Q., Galloway D., et al. Serum antibody response following genital alpha9 human papillomavirus infection in young men. Journal of Infectious Diseases 2011, 204:209-216.
41. Carter J., Koutsky L., Hughes J., Kuang Lee S., Kuypers J., Kiviat N., et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. Journal of Infectious Diseases 2000, 181:1911-1919.
42. Lu B., Hagensee M., Lee J., Wu Y., Stockwell H., Nielson C., et al. Epidemiologic factors associated with seropositivity to human papillomavirus type 16 and 18 virus-like particles and risk of subsequent infection in men. Cancer Epidemiology, Biomarkers and Prevention 2010, 19:511-516.